|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.
|
|
3
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.
|
|
4
|
Mountain CF, Lukeman JM, Hammar SP,
Chamberlain DW, Coulson WF, Page DL, Victor TA and Weiland LH: Lung
cancer classification: The relationship of disease extent and cell
type to survival in a clinical trials population. J Surg Oncol.
35:147–156. 1987.
|
|
5
|
Curtis SJ, Sinkevicius KW, Li D, Lau AN,
Roach RR, Zamponi R, Woolfenden AE, Kirsch DG, Wong K-K and Kim CF:
Primary tumor genotype is an important determinant in
identification of lung cancer propagating cells. Cell Stem Cell.
7:127–133. 2010.
|
|
6
|
Tan BT, Park CY, Ailles LE and Weissman
IL: The cancer stem cell hypothesis: A work in progress. Lab
Invest. 86:1203–1207. 2006.
|
|
7
|
Gil J, Stembalska A, Pesz KA and Sasiadek
MM: Cancer stem cells: The theory and perspectives in cancer
therapy. J Appl Genet. 49:193–199. 2008.
|
|
8
|
Li L and Neaves WB: Normal stem cells and
cancer stem cells: The niche matters. Cancer Res. 66:4553–4557.
2006.
|
|
9
|
Mukherjee S, Kong J and Brat DJ: Cancer
stem cell division: When the rules of asymmetry are broken. Stem
Cells Dev. 24:405–416. 2015.
|
|
10
|
Chen S and Huang EH: The colon cancer stem
cell microenvironment holds keys to future cancer therapy. J
Gastrointest Surg. 18:1040–1048. 2014.
|
|
11
|
O'Flaherty JD, Barr M, Fennell D, Richard
D, Reynolds J, O'Leary J and O'Byrne K: The cancer stem-cell
hypothesis: Its emerging role in lung cancer biology and its
relevance for future therapy. J Thorac Oncol. 7:1880–1890.
2012.
|
|
12
|
Hong IS, Lee HY and Nam JS: Cancer stem
cells: The 'Achilles heel' of chemo-resistant tumors. Recent
Patents Anticancer Drug Discov. 10:2–22. 2015.
|
|
13
|
Orian-Rousseau V and Ponta H: Perspectives
of CD44 targeting therapies. Arch Toxicol. 89:3–14. 2015.
|
|
14
|
Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi
Y, Wu X, Cheng L, Ma C, Xia J, et al: Curcumin inhibits cell growth
and invasion through up-regulation of miR-7 in pancreatic cancer
cells. Toxicol Lett. 231:82–91. 2014.
|
|
15
|
Mukherjee S, Mazumdar M, Chakraborty S,
Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A,
Mukhjerjee S, et al: Curcumin inhibits breast cancer stem cell
migration by amplifying the E-cadherin/β-catenin negative feedback
loop. Stem Cell Res Ther. 5:1162014.
|
|
16
|
Sarkar R, Mukherjee A, Mukherjee S, Biswas
R, Biswas J and Roy M: Curcumin augments the efficacy of antitumor
drugs used in leukemia by modulation of heat shock proteins via
HDAC6. Environ Pathol Toxicol Oncol. 33:247–263. 2014.
|
|
17
|
Xiao C, Wang L, Zhu L, Zhang C and Zhou J:
Curcumin inhibits oral squamous cell carcinoma SCC-9 cells
proliferation by regulating miR-9 expression. Biochem Biophys Res
Commun. 454:576–580. 2014.
|
|
18
|
Ye M and Zhang J and Zhang J, Miao Q, Yao
L and Zhang J: Curcumin promotes apoptosis by activating the
p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.
Cancer Lett. 357:196–205. 2015.
|
|
19
|
Anand P, Sundaram C, Jhurani S,
Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: An 'old-age'
disease with an 'age-old' solution. Cancer Lett. 267:133–164.
2008.
|
|
20
|
Andjelkovic T, Pesic M, Bankovic J, Tanic
N, Markovic ID and Ruzdijic S: Synergistic effects of the purine
analog sulfinosine and curcumin on the multidrug resistant human
non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol
Ther. 7:1024–1032. 2008.
|
|
21
|
Ebert B, Seidel A and Lampen A:
Phytochemicals induce breast cancer resistance protein in Caco-2
cells and enhance the transport of benzo(a)pyrene-3-sulfate.
Toxicol Sci. 96:227–236. 2007.
|
|
22
|
Hou X-L, Takahashi K, Tanaka K, Tougou K,
Qiu F, Komatsu K, Takahashi K and Azuma J: Curcuma drugs and
curcumin regulate the expression and function of P-gp in Caco-2
cells in completely opposite ways. Int J Pharm. 358:224–229.
2008.
|
|
23
|
Chanvorachote P, Pongrakhananon V,
Wannachaiyasit S, Luanpitpong S, Rojanasakul Y and Nimmannit U:
Curcumin sensitizes lung cancer cells to cisplatin-induced
apoptosis through superoxide anion-mediated Bcl-2 degradation.
Cancer Invest. 27:624–635. 2009.
|
|
24
|
Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H
and Jiang L: Curcumin lowers erlotinib resistance in non-small cell
lung carcinoma cells with mutated EGF receptor. Oncol Res.
21:137–144. 2013.
|
|
25
|
Chan MM, Fong D, Soprano KJ, Holmes WF and
Heverling H: Inhibition of growth and sensitization to
cisplatin-mediated killing of ovarian cancer cells by polyphenolic
chemopreventive agents. J Cell Physiol. 194:63–70. 2003.
|
|
26
|
Chan MM, Soprano KJ, Weinstein K and Fong
D: Epigallo catechin-3-gallate delivers hydrogen peroxide to induce
death of ovarian cancer cells and enhances their cisplatin
susceptibility. J Cell Physiol. 207:389–396. 2006.
|
|
27
|
Duarte VM, Han E, Veena MS, Salvado A, Suh
JD, Liang LJ, Faull KF, Srivatsan ES and Wang MB: Curcumin enhances
the effect of cisplatin in suppression of head and neck squamous
cell carcinoma via inhibition of IKKβ protein of the NFκB pathway.
Mol Cancer Ther. 9:2665–2675. 2010.
|
|
28
|
Notarbartolo M, Poma P, Perri D, Dusonchet
L, Cervello M and D'Alessandro N: Antitumor effects of curcumin,
alone or in combination with cisplatin or doxorubicin, on human
hepatic cancer cells. Analysis of their possible relationship to
changes in NF-κB activation levels and in IAP gene expression.
Cancer Lett. 224:53–65. 2005.
|
|
29
|
Aggarwal BB, Shishodia S, Takada Y,
Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin
suppresses the paclitaxel-induced nuclear factor-kappaB pathway in
breast cancer cells and inhibits lung metastasis of human breast
cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005.
|
|
30
|
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF,
Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I
clinical trial of curcumin, a chemopreventive agent, in patients
with high-risk or pre-malignant lesions. Anticancer Res.
21:2895–2900. 2001.
|
|
31
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007.
|
|
32
|
Kakarala M, Brenner DE, Korkaya H, Cheng
C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS: Targeting
breast stem cells with the cancer preventive compounds curcumin and
piperine. Breast Cancer Res Treat. 122:777–785. 2010.
|
|
33
|
Fong D, Yeh A, Naftalovich R, Choi TH and
Chan MM: Curcumin inhibits the side population (SP) phenotype of
the rat C6 glioma cell line: Towards targeting of cancer stem cells
with phytochemicals. Cancer Lett. 293:65–72. 2010.
|
|
34
|
Zhuang W, Long L, Zheng B, Ji W, Yang N,
Zhang Q and Liang Z: Curcumin promotes differentiation of
glioma-initiating cells by inducing autophagy. Cancer Sci.
103:684–690. 2012.
|
|
35
|
Pellacani D, Oldridge EE, Collins AT and
Maitland NJ: Prominin-1 (CD133) expression in the prostate and
prostate cancer: A marker for quiescent stem cells. Adv Exp Med
Biol. 777:167–184. 2013.
|
|
36
|
Reyes EE, Kunovac SK, Duggan R, Kregel S
and Vander Griend DJ: Growth kinetics of CD133-positive prostate
cancer cells. Prostate. 73:724–733. 2013.
|
|
37
|
Vander Griend DJ, Karthaus WL, Dalrymple
S, Meeker A, DeMarzo AM and Isaacs JT: The role of CD133 in normal
human prostate stem cells and malignant cancer-initiating cells.
Cancer Res. 68:9703–9711. 2008.
|
|
38
|
Bi CL, Fang JS, Chen FH, Wang YJ and Wu J:
Chemoresistance of CD133(+) tumor stem cells from human brain
glioma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32:568–573. 2007.In
Chinese.
|
|
39
|
Choi SA, Wang KC, Phi JH, Lee JY, Park CK,
Park SH and Kim SK: A distinct subpopulation within CD133 positive
brain tumor cells shares characteristics with endothelial
progenitor cells. Cancer Lett. 324:221–230. 2012.
|
|
40
|
Li MC, Deng YW, Wu J, Chen FH, Liu JF and
Fang JS: Isolation and characterization of brain tumor stem cells
in human medulloblastoma. Ai Zheng. 25:241–246. 2006.In
Chinese.
|
|
41
|
Singh S and Dirks PB: Brain tumor stem
cells: Identification and concepts. Neurosurg Clin N Am. 18:31–38.
2007.
|
|
42
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: Cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014.
|
|
43
|
Mărgaritescu C, Pirici D, Cherciu I,
Bărbălan A, Cârtână T and Săftoiu A: CD133/CD166/Ki-67 triple
immunofluorescence assessment for putative cancer stem cells in
colon carcinoma. J Gastrointestin Liver Dis. 23:161–170. 2014.
|
|
44
|
Vincent Z, Urakami K, Maruyama K,
Yamaguchi K and Kusuhara M: CD133-positive cancer stem cells from
Colo205 human colon adenocarcinoma cell line show resistance to
chemotherapy and display a specific metabolomic profile. Genes
Cancer. 5:250–260. 2014.
|
|
45
|
Cogliati B, Aloia TP, Bosch RV, Alves VA,
Hernandez-Blazquez FJ and Dagli ML: Identification of hepatic
stem/progenitor cells in canine hepatocellular and
cholangiocellular carcinoma. Vet Comp Oncol. 8:112–121. 2010.
|
|
46
|
Tomuleasa C, Soritau O, Rus-Ciuca D, Pop
T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G, et
al: Isolation and characterization of hepatic cancer cells with
stem-like properties from hepatocellular carcinoma. J
Gastrointestin Liver Dis. 19:61–67. 2010.
|
|
47
|
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi
GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al: High expression levels of
putative hepatic stem/progenitor cell biomarkers related to tumour
angio-genesis and poor prognosis of hepatocellular carcinoma. Gut.
59:953–962. 2010.
|
|
48
|
Zhang L, Sun H, Zhao F, Lu P, Ge C, Li H,
Hou H, Yan M, Chen T, Jiang G, et al: BMP4 administration induces
differentiation of CD133+ hepatic cancer stem cells,
blocking their contributions to hepatocellular carcinoma. Cancer
Res. 72:4276–4285. 2012.
|
|
49
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S,
et al: Highly tumor-igenic lung cancer CD133+ cells
display stem-like features and are spared by cisplatin treatment.
Proc Natl Acad Sci USA. 106:16281–16286. 2009.
|
|
50
|
Salnikov AV, Gladkich J, Moldenhauer G,
Volm M, Mattern J and Herr I: CD133 is indicative for a resistance
phenotype but does not represent a prognostic marker for survival
of non-small cell lung cancer patients. Int J Cancer. 126:950–958.
2010.
|
|
51
|
Sullivan JP, Spinola M, Dodge M, Raso MG,
Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et
al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma
stem cells dependent on notch signaling. Cancer Res. 70:9937–9948.
2010.
|
|
52
|
Woo T, Okudela K, Mitsui H, Yazawa T,
Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H and Masuda M:
Prognostic value of CD133 expression in stage I lung
adenocarcinomas. Int J Clin Exp Pathol. 4:32–42. 2010.
|
|
53
|
Sterlacci W, Savic S, Fiegl M, Obermann E
and Tzankov A: Putative stem cell markers in non-small-cell lung
cancer: A clini-copathologic characterization. J Thorac Oncol.
9:41–49. 2014.
|
|
54
|
Zhang WC, Shyh-Chang N, Yang H, Rai A,
Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, et al: Glycine
decarboxylase activity drives non-small cell lung cancer
tumor-initiating cells and tumorigenesis. Cell. 148:259–272.
2012.
|
|
55
|
Zakaria N, Yusoff NM, Zakaria Z, Lim MN,
Baharuddin PJN, Fakiruddin KS and Yahaya B: Human non-small cell
lung cancer expresses putative cancer stem cell markers and
exhibits the transcriptomic profile of multipotent cells. BMC
Cancer. 15:842015.
|
|
56
|
Chen K, Huang YH and Chen JL:
Understanding and targeting cancer stem cells: Therapeutic
implications and challenges. Acta Pharmacol Sin. 34:732–740.
2013.
|
|
57
|
Xu X-M, Zhang Y, Qu D, Liu H-B, Gu X, Jiao
G-Y and Zhao L: Combined anticancer activity of osthole and
cisplatin in NCI-H460 lung cancer cells in vitro. Exp Ther
Med. 5:707–710. 2013.
|
|
58
|
Douillard J-Y, Eckardt J and Scagliotti
GV: Challenging the platinum combinations in the chemotherapy of
NSCLC. Lung Cancer. 38(Suppl 4): 21–28. 2002.
|
|
59
|
Stewart DJ: Mechanisms of resistance to
cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31.
2007.
|
|
60
|
Burnett J, Newman B and Sun D: Targeting
cancer stem cells with natural products. Curr Drug Targets.
13:1054–1064. 2012.
|
|
61
|
Mondal S, Bandyopadhyay S, Ghosh MK,
Mukhopadhyay S, Roy S and Mandal C: Natural products: Promising
resources for cancer drug discovery. Anticancer Agents Med Chem.
12:49–75. 2012.
|
|
62
|
Ye MX, Zhao YL, Li Y, Miao Q, Li ZK, Ren
XL, Song LQ, Yin H and Zhang J: Curcumin reverses cisplatin
resistance and promotes human lung adenocarcinoma A549/DDP cell
apoptosis through HIF-1alpha and caspase-3 mechanisms.
Phytomedicine. 19:779–787. 2012.
|
|
63
|
Zhou B-BS, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009.
|
|
64
|
Buhrmann C, Kraehe P, Lueders C, Shayan P,
Goel A and Shakibaei M: Curcumin suppresses crosstalk between colon
cancer stem cells and stromal fibroblasts in the tumor
microen-vironment: Potential role of EMT. PLoS One.
9:e1075142014.
|
|
65
|
Charpentier MS, Whipple RA, Vitolo MI,
Boggs AE, Slovic J, Thompson KN, Bhandary L and Martin SS: Curcumin
targets breast cancer stem-like cells with microtentacles that
persist in mammospheres and promote reattachment. Cancer Res.
74:1250–1260. 2014.
|
|
66
|
Wang X, Zhu Y, Ma Y, Wang J, Zhang F, Xia
Q and Fu D: The role of cancer stem cells in cancer metastasis: New
perspective and progress. Cancer Epidemiol. 37:60–63. 2013.
|
|
67
|
Fazilaty H, Gardaneh M, Bahrami T,
Salmaninejad A and Behnam B: Crosstalk between breast cancer stem
cells and metastatic niche: Emerging molecular metastasis pathway?
Tumour Biol. 34:2019–2030. 2013.
|
|
68
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009.
|
|
69
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
|
|
70
|
Srivastava RK, Chen Q, Siddiqui I, Sarva K
and Shankar S: Linkage of curcumin-induced cell cycle arrest and
apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1).
Cell Cycle. 6:2953–2961. 2007.
|
|
71
|
Zhang H, Yu T, Wen L, Wang H, Fei D and
Jin C: Curcumin enhances the effectiveness of cisplatin by
suppressing CD133(+) cancer stem cells in laryngeal carcinoma
treatment. Exp Ther Med. 6:1317–1321. 2013.
|
